Patents Assigned to Bristol-Myers Squibb Company
  • Publication number: 20220144962
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 12, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
  • Publication number: 20220135619
    Abstract: The disclosure provides a method of separating a protein product, e.g., from a contaminant in a mixture, comprising contacting the mixture with a polishing chromatography matrix. In some embodiments, the polishing chromatography matrix is used together with a retained gradient. In certain embodiments, the retained gradient comprises a pH gradient. In certain embodiments, the mixture comprises a monoclonal antibody product of a prior protein A chromatography.
    Type: Application
    Filed: February 24, 2020
    Publication date: May 5, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Douglas D. FREY, Yang LIU, Sevda DELDARI, Ryan Keith SWANSON, Chittoor R. NARAHARI, Ronald Charles BATES, Sanchayita GHOSE, Zhengjian LI
  • Publication number: 20220135685
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: November 10, 2021
    Publication date: May 5, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Patent number: 11319315
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 3, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Li, Tianan Fang, James R. Corte, Jun Shi, Hao Zhang, Lawrence J. Kennedy, Shiwei Tao
  • Patent number: 11319309
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 3, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng
  • Patent number: 11312777
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 26, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle R. Kuhne, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
  • Patent number: 11312706
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 26, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Li, Steven J. Walker
  • Patent number: 11306092
    Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein G, R1, R5, R7, R8, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, David R. Tortolani, Tasir Shamsul Haque, Shoshana L. Posy
  • Patent number: 11306143
    Abstract: Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody).
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: April 19, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sean E. Doyle, Mark J. Selby, Eric Chadwick
  • Patent number: 11306149
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • Patent number: 11306150
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • Patent number: 11306081
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto
  • Patent number: 11299494
    Abstract: Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: April 12, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John V. Duncia, Steven H. Spergel
  • Patent number: 11299488
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 12, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Tarun Kumar Maishal
  • Patent number: 11299501
    Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, X, Y, Z, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 12, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Brian K. Whiteley, Sreekantha Ratna Kumar, Anupama Kandhi Ramachandra Reddy
  • Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • Patent number: 11292802
    Abstract: The disclosure relates to compounds of formula I: Formula I which inhibit ?V-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 5, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guohua Zhao, James Mignone
  • Publication number: 20220099637
    Abstract: This disclosure provides several methods in LC-MS/MS analysis: (1) a method of LC-MS/MS analysis technique to determine the analyte concentration of a sample wherein an In-Sample Calibration Curve (ISCC) is used instead of an external calibration curve through monitoring of multiple isotopologue transitions of an added stable isotopically labeled (SIL) analyte in each sample via MS/MS in multiple isotopologue reaction monitoring (MIRM) mode; (2) a method of LC-MS/MS analysis to determine the analyte concentration of a sample wherein a One-Sample Multipoint External Calibration Curve (OSMECC) is used instead of a multisample external calibration curve; and (3) a method of LC-MS/MS analysis to determine the analyte concentration of a sample with an analyte concentration beyond the assay's ULOQ wherein isotope sample dilution is used instead of diluting sample physically during sample preparation based on calculating the isotopic abundance of the MIRM channel monitored.
    Type: Application
    Filed: December 3, 2019
    Publication date: March 31, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Huidong GU, Yue ZHAO, Jianing ZENG
  • Patent number: 11286252
    Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 29, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jianxin Feng, Chunjian Liu, Yanting Huang
  • Publication number: 20220089734
    Abstract: Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 24, 2022
    Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Kimberly Ann TIPTON, James William WEST, Shrikant DESHPANDE, John J. ENGLEHARDT